Introduction: Study 303 (SUNRISE-2; NCT02952820) evaluated lemborexant (LEM) efficacy in subjects with insomnia. This post-hoc analysis examined sleep outcomes in the subgroup of subjects...
INTRODUCTION: The insomnia severity index (ISI) is a self-report instrument that evaluates perception of insomnia severity. In Study 303 (SUNRISE-2), lemborexant (LEM) showed greater red...
Introduction: Lemborexant is approved in the US for treating insomnia in adults. We evaluated the evidence-base for lemborexant and suvorexant, both dual orexin receptor antagonists (DORA...
Introduction: The Fatigue Severity Scale (FSS) assesses impact of fatigue on patients’ lives. Lemborexant (LEM) efficacy was examined in the subgroup of subjects with baseline FSS total s...